Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cytrx Corp receives FDA approval to extend aldoxorubicin dosing cycles until disease progression in upcoming pivotal, global phase 3 trial for soft tissue sarcomas


Tuesday, 21 Jan 2014 06:30am EST 

Cytrx Corp:Says it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.Says the clinical trial is scheduled to begin this quarter.Says for purposes of the clinical trial, disease progression is defined as an increase in the size of measurable tumors by 20% or the development of a new tumor lesion. 

Company Quote

2.56
0.24 +10.34%
18 Dec 2014